This seminar is a fantastic opportunity to hear from leading researchers about novel therapeutic pathways that could revolutionise the treatment of diabetes and liver disease
Event Details:
Topic:ÌýDiabetes and Liver Disease: Novel Pathways for Therapeutic Innovation
Date:Ìý30th September 2024
Time:Ìý1:00 PM - 2:00 PM
Location:ÌýAinsworth 102, ÁñÁ«¹ÙÍø (Hybrid event - Join via Ìýif you can't attend in person)
Speakers:
Host:
Daisy Shu, PhD
Scientia Senior Lecturer, ÁñÁ«¹ÙÍø School of Optometry and Vision Science
This seminar is a fantastic opportunity to hear from leading researchers about novel therapeutic pathways that could revolutionise the treatment of diabetes and liver disease.
For more details, visit our .
To join the seminar via Zoom, please scan the QR code on the attached flyer or click .
Roberto Mota
Talk title
HMGB1 as a therapeutic target in Type-2 DiabetesÌý
Biography
Dr. Mota Alvidrez is an Assistant Professor (Tenure track) in the Department of Pharmaceutical Sciences at the University of New Mexico College of Pharmacy. Dr. Mota Alvidrez is also a KL2-funded scholar from the NCATS in the Clinical and Translational Science Center at the University of New Mexico. Dr. Mota Alvidrez works in basic and translational research focusing on the consequences of diabetic disease in cardiovascular and metabolic function, particularly atherothrombosis. His research program focuses on understanding the molecular mechanisms that guide why diabetic patients have worst and accelerated vascular atherosclerosis with life-threatening complications in sex-specific disease progression. His research has helped develop the first diabetic, atherosclerotic, obese, and dyslipidemic rat model and a non-invasive, longitudinal pre-clinical SPECT/CT imaging tool to evaluate inflammation in atherosclerosis externally. Dr. Mota Alvidrez’s research program identifies timely and accurate preclinical diagnostic modalities in diabetic vasculopathy that can be translated to the clinic. His research program also focuses on identifying therapeutic targets, vascular drug delivery, and immunotherapies in the still unresolved and important biomedical problem of diabetic vasculopathy.
Ìý
Vik Meadows PhD
Postdoctoral Fellow, Rutgers University
Talk title
Follow the gut-liver axis: how Ruminococcus gnavus can alter hepatic steatosis
Bio: Dr. Vik Meadows is a Presidential Postdoctoral Fellow in Pharmacology, Physiology and Neuroscience at Rutgers New Jersey Medical School . Vik holds a PhD in Biochemistry and Molecular Biology from Indiana University and a MS from Oregon Health & Science University. Her research interests center on the gut-liver axis and how gut physiology, the gut microbiome, and liver function orchestrate communication within. She is currently studying how paneth cells and mucolytic bacteria affect liver function through alterations of the gut-liver axis.Ìý Vik has been funded by the Rutgers IRACDA-INSPIRE Postdoctoral Fellowship (NIGMS), Pharmacology & Toxicology T32 training grant (NIEHS) and the Mistletoe Research Fellowship for 2022-2023. Additionally, Vik was recognized as a 2022-2023 Postdoctoral Scala Scholar for work on organ-specific FXR function in Grace Guo, M.B.B.S, Ph.D.’s lab. Vik is dedicated to science communication and mentoring, co-founding the Biochem Chat Diversity Seminar and serving as co-host to the Behind Our Science podcast, and works to shatter barriers for the next generation to study science.
